Ghisallo Capital Management’s Vaxcyte PCVX Stock Holding History

Ghisallo Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,000	Closed	-$1.45M	–	363
2026 Q1	$1.45M	Buy	+25,000	New	+$1.36M	0.04%	219

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ghisallo Capital Management's PCVX Position: Q2 2026 in Review

Ghisallo Capital Management sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 25,000 shares — an estimated $1.45M sold.

Ghisallo Capital Management first reported a position in PCVX in Q1 2026 and held it in 1 quarter. The position peaked at $1.45M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Ghisallo Capital Management reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
Ghisallo Capital Management sold 25,000 Vaxcyte shares in Q2 2026, an estimated $1.45M.
Ghisallo Capital Management first reported a position in Vaxcyte in Q1 2026 and held it in 1 quarter.
Ghisallo Capital Management's Vaxcyte position peaked at $1.45M in Q1 2026.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Ghisallo Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.